The medical impact of hepatitis D virus infection in Uzbekistan

Background & Aims The hepatitis B virus (HBV) is endemic in Uzbekistan but the medical impact of infection with the HBV‐dependent hepatitis D virus (HDV) is unknown in the Country. An Hepatology Center was recently established at the Institute of Virology in Tashkent, which has set up a database...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2019-11, Vol.39 (11), p.2077-2081
Main Authors: Khodjaeva, Malika, Ibadullaeva, Nargiz, Khikmatullaeva, Aziza, Joldasova, Elizaveta, Ismoilov, Umed, Colombo, Massimo, Caviglia, Gian Paolo, Rizzetto, Mario, Musabaev, Erkin
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Cirrhosis
epidemiology
HBV
HDV
Hepatitis
Hepatitis B
Hepatitis B surface antigen
Hepatitis C
Hepatitis delta virus
Infections
Liver
Liver cirrhosis
Liver diseases
Superinfection
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims The hepatitis B virus (HBV) is endemic in Uzbekistan but the medical impact of infection with the HBV‐dependent hepatitis D virus (HDV) is unknown in the Country. An Hepatology Center was recently established at the Institute of Virology in Tashkent, which has set up a database enlisting patients with chronic viral liver disorders from all over Uzbekistan; it provides an observatory on the current scenario of viral hepatitis in the Country. Methods The prevalence of HBV monoinfection, hepatitis C virus (HCV) infection and HDV superinfection on hepatitis B surface antigen (HBsAg)‐positive cirrhosis was determined in 6589 patients with viral cirrhosis collected in the last 3 years. Results Of 1089, 1150 and 1455 carriers of the HBsAg with cirrhosis recruited in 2016, 2017 and 2018, 834 (76.5%), 926 (80.5%) and 1224 (84%) respectively, had antibody to the HDV. In 2016, 2017 and 2018, the prevalence of HDV infection has been 41%, 45% and 49.1% respectively, largely exceeding the prevalence of HBV monoinfection (12.5%, 11% and 9.3% respectively) and surpassing the prevalence of HCV in 2017 and 2018 (44% and 41.5% respectively). The median age of the patients with HDV cirrhosis was 39 years, distinctly lower than that of HBV and HCV patients (46 and 55). Conclusions Superinfection with the HDV is present in over 80% of the HBsAg‐positive cirrhosis in Uzbekistan. The HDV appears to be the major cause of advanced viral liver disease and of juvenile cirrhosis in the Country. See Editorial on Page 2034
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14243